• LAST PRICE
    9.7000
  • TODAY'S CHANGE (%)
    Trending Down-0.0600 (-0.6148%)
  • Bid / Lots
    9.6900/ 25
  • Ask / Lots
    9.7000/ 8
  • Open / Previous Close
    9.6700 / 9.7600
  • Day Range
    Low 9.5700
    High 9.8900
  • 52 Week Range
    Low 3.2100
    High 18.3300
  • Volume
    689,093
    average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Wednesday's close: 9.76
TimeVolumeIOVA
09:32 ET365639.73
09:34 ET174059.66
09:36 ET53699.7419
09:38 ET175329.74
09:39 ET192129.8
09:41 ET168459.77
09:43 ET166959.81
09:45 ET318819.685
09:48 ET145249.685
09:50 ET84749.605
09:52 ET401159.63
09:54 ET47579.625
09:56 ET394369.61
09:57 ET285759.5942
09:59 ET313389.6098
10:01 ET182319.645
10:03 ET62969.68
10:06 ET54029.655
10:08 ET44209.6635
10:10 ET120459.67
10:12 ET85719.66
10:14 ET104759.645
10:15 ET234379.605
10:17 ET100849.61
10:19 ET310949.675
10:21 ET149289.7
Data delayed at least 15 minutes.
0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesIOVA
Iovance Biotherapeutics Inc
3.0B
-5.8x
---
United StatesXENE
Xenon Pharmaceuticals Inc
3.1B
-14.9x
---
United StatesVSBC
Vitaspring Biomedical Co. Ltd
3.1B
3,311.3x
---
United StatesGERN
Geron Corp
2.7B
-12.2x
---
United StatesAPGE
Apogee Therapeutics Inc
3.3B
-25.0x
---
United StatesMLTX
MoonLake Immunotherapeutics
3.3B
-56.8x
---
As of 2024-10-03

Company Information

Iovance Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company develops and delivers tumor infiltrating lymphocyte (TIL), therapies for patients with solid tumor cancers. Its lead product candidate, Amtagvi (lifileucel), is a tumor-derived autologous T cell immunotherapy indicated for the treatment of adult patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor with or without a MEK inhibitor. The Company also marketing Proleukin (aldesleukin), aninterleukin-2, or IL-2, product used in the Amtagvi treatment regimen. Its development pipeline includes multicenter trials of TIL cell therapies in additional treatment settings for solid tumor cancers. Amtagvi and Proleukin are part of a treatment regimen that also includes lymphodepletion. The Company is also developing next generation therapies using TIL, such as genetically modified TIL cell therapy.

Contact Information

Headquarters
825 INDUSTRIAL ROAD, 4TH FLOORSAN CARLOS, CA, United States 94070
Phone
650-260-7120
Fax
302-697-4597

Executives

Independent Chairman of the Board
Iain Dukes
Interim President, Interim Chief Executive Officer, General Counsel, Corporate Secretary
Frederick Vogt
Chief Financial Officer
Jean-Marc Bellemin
Chief Operating Officer
Igor Bilinsky
Chief Medical Officer
Friedrich Graf Finckenstein

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$3.0B
Revenue (TTM)
$32.8M
Shares Outstanding
303.5M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.60
EPS
$-1.68
Book Value
$2.28
P/E Ratio
-5.8x
Price/Sales (TTM)
90.4
Price/Cash Flow (TTM)
---
Operating Margin
-1,401.36%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.